Eisai, Biogen continuing AD trial despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to treat prodromal

Read the full 377 word article

User Sign In